View Document Preview and Link Document Date: 2014-05-20 20:49:04 Open Document File Size: 612,70 KB Share Result on Facebook
Company CVS / / Continent Europe / / Country United States / Canada / Australia / United Kingdom / New Zealand / / Event Product Issues / Product Recall / FDA Phase / / Facility Pharmacy Guild / Pharmacy Today / Pharmacy Retailing / / IndustryTerm treatment of insomnia / machinery / medical solution / immediate release product / manufacturing quality / pharmaceutical regulatory approval process / registered products / / MedicalCondition insomnia / hypertension / headache / nasopharyngitis / Currently available insomnia / amnesia / Chronic use / change Insomnia / cognitive impairment / primary insomnia / secondary insomnia / drowsiness / daytime fatigue / occasional sleeplessness / hypersensitivity / chronic insomnia / Withdrawal symptoms / sleep disorders / depression / primary sleep disorders / back pain / disorders / autoimmune diseases / had training in sleep disorders / / MedicalTreatment dietary supplement / oral contraceptives / Home remedies / Herbal remedies / / Organization Concomitant administration / Pharmaceutical Society of NZ / Natural Health Products Directorate of Health Canada / College of Pharmacists / European Union / Pharmacy Guild of NZ / Medicines Classification Committee / / Person Benjamin Mahon / / Position pharmacist / general sales classification statement / / Product symptoms / 5mg / CIRCADIN tablets / carbamazepine / temazepam / triazolam / cimetidine / nifedipine / zolpidem / the effect / memory / NZ / / PublishedMedium the Best Practice Journal / / SocialTag 
Submission for Reclassification of Melatonin Executive Summary This application is seeking the reclassification of melatonin in prolonged release 2mg oral dose form to Restricted Medicine (Pharmacist-Only Medicine). Mela